Physicians  |  Vendors  |  Patients  |  Employees

 
 
 
News
 
Mayo Clinic Cancer Center & Florida Hospital Waterman Join Forces

June 20, 2011

 

Contact:  Bonnie Zimmerman
Director, Marketing and Physician Services
Florida Hospital Waterman
1000 Waterman Way
Tavares, FL  32778
(352) 253-3442

News for Immediate Release



Tavares, FL:  Mayo Clinic Cancer Center is pleased to announce the enrollment of Florida Hospital Waterman Cancer Institute (FHWCI) as a member of the North Central Cancer Treatment Group (NCCTG).  With this enrollment, FHWCI becomes an affiliate site to Mayo Clinic of Florida. Mayo Clinic serves as the research base for NCCTG, providing clinical and laboratory research expertise including clinical trial development, treatment and data analysis.

The doctors of Lake County Oncology and Hematology (Dr. Maen Hussein, Dr. Ralph Gousse, and Dr. Ahmed Al-Hazzouri) have volunteered to perform as Investigators for these clinical trials at FHWCI.  “As Investigator, it is my responsibility to adhere to the design of the trial so that patient outcomes can be compared to other standards of care to see if this new treatment regimen is better than our existing standard of care,” says Dr. Hussein.  “It is exciting to be part of a successful new drug or treatment that advances my patients’ health and lives.”  The clinical trials team consists of these doctors, nurses, coordinators, radiologist and pathologist, social worker and other health care practitioners who monitor patients’ care during and after the study.

Participation in a clinical trial is always voluntary. Participants are given an Informed Consent to review and discuss with the study staff, friends and family before deciding to participate, and whenever study staff learn new information participants are informed. Safety at all levels is a paramount tenet of clinical trials engagement.

“With people taking an active role in their healthcare and in collaborating with our research team, we can continue to improve health and fight diseases such as cancer,” says Dr. Hussein.  “Much of the decline in cancer mortality rates over the last ten years is directly attributable to new care outcomes advanced through Clinical Trials.”

FHWCI is proud to offer promising new drug and cancer therapies to those afflicted with cancer. We currently have trials in pancreas, breast cancer, leukemia, myelodysplastic syndrome, and mucositis in head and neck cancer, and we offer disease registries for multiple myeloma, and leukemia.




##################